BioCryst Pharmaceuticals | BCRX - Ebitda


BioCryst Pharmaceuticals reported $51.7M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Chugai Pharma JPY 158.77B 10.24B Mar/2026
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
DBV Technologies USD -45.9M 12.42M Mar/2026
Gilead Sciences USD 3.51B 489M Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Glaxosmithkline GBP 2.77B 1.98B Mar/2026
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novavax USD 19.36M 190.79M Dec/2025
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026